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Abstract
Purpose: To compare the efficacy of two independent groups of patients treated with ultrasound (US)-guided
extracorporeal shock wave (ESW) therapy and with US-guided injection of platelet-rich plasma (PRP) for chronic
lateral epicondylitis (LE) with a minimum of 2-year follow-up. Methods: We retrospectively evaluated 63 patients
treated for chronic LE (31 patients with autologous US-guided PRP injection and 32 patients with US-guided focal ESW
therapy) from 2009 to 2014. All the patients were evaluated by means of Roles–Maudsley (RM) score, quick Disabilities of
Arm, Shoulder, and Hand (QuickDASH) score, visual analogic scale (VAS) and patient-rated tennis elbow evaluation
(PRTEE) to retrospectively assess the pain relief, level of activity, the self-reported function and subjective satisfaction at
minimum of 2-year follow-up. Results: Both US-guided autologous PRP injection and US-guided focal ESW adminis-
tration proved effective in chronic LE with significant improvement in the QuickDASH, VAS, RM and PRTEE scores (p <
0.0001). No adverse effects or complications were recorded in any groups. No differences were found in recurrence
rate and final results of the QuickDASH, VAS, RM and PRTEE scores between the two groups (p > 0.05). The mean time
between treatment and symptom resolution was significantly shorter for the PRP treatment (p¼ 0.0212); furthermore,
the mean time to return to the normal activities was quicker for PRP group (p ¼ 0.0119). Conclusion: Both PRP
injection and ESW therapy are feasible and safe options for the treatment of chronic LE with low risk of complications and
with good long-term follow-up results. US-guided PRP injection has quick efficacy when compared with US-guided focal
ESW therapy.
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Introduction
Lateral epicondylitis (LE) is a painful condition of the
elbow, resulting from a non-inflammatory tendinopathy
along the extensor origin of the lateral epicondyle.1 It
affects 1–3% of the adult population and most commonly
presents in the fourth and fifth decades of life, with equal
prevalence among males and females.2 Multiple aetiologies
have been proposed, including micro-tears between the
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tendon origin of extensor carpi radialis brevis (ECRB) and
the periosteum of the lateral epicondyle that lead to both
inflammation and degenerative changes.3 It has been
demonstrated that the common extensor origin of the lateral
epicondyle region is vulnerable to micro-traumatic events
from eccentric loading and overuse because of its poor
vascular supply.4 Patients report pain and tenderness on the
lateral aspect of the elbow with weakness in wrist extension
and impairment of the gripping activities. A wide variety of
therapies have been proposed (i.e. rest, physical therapy,
non-steroidal anti-inflammatory medication, bracing and
local injection) but the choice of the best treatment is still
debated.1–3 In case of failure of conservative measures, in
5–15% of patients surgery is required and the reported
success rate of surgery is 85%.5
Extracorporeal shock waves (ESWs) are transient pres-
sure oscillations that propagated in three dimensions and
directly stimulate the healing, neovascularization and sup-
pression of the activity of nociceptors on the target tissue.
ESW treatment can increase the neovessels at the normal
tendon–bone junction through the release of growth factors,
transforming growth factor (TGFb-1) and Insuline-like
growth factor (IGF-I).6 Clinical application of ultrasound
(US)-guided focal ESW demonstrated good short- to mid-
term results for the treatment of LE.7–9
On the other hand, several major preclinical and clin-
ical studies have examined the role and therapeutic effects
of platelet-rich plasma (PRP) in the treatment of soft tis-
sue pathologies and other musculoskeletal disorders.10–12
Platelets contain more than 300 bioactive cytokines and
growth factors that operate via paracrine and autocrine
mechanisms to coordinate cellular communication.
Platelets also release vasoactive substances such as sero-
tonin, calcium, histamine, and adenosine via their dense
granules.11
Although the fullness of literature of studies focused on
the conservative treatment of LE, there are no paper com-
paring the long-term efficacy and the clinical outcome of
the focal ESW therapy and PRP injection.
The aim of this study was to compare the efficacy of two
independent groups of patients treated with US-guided
ESW therapy and with US-guided injection of PRP for
chronic LE with a minimum of 2-year follow-up.
Materials and methods
We retrospectively evaluated 63 patients (63 elbows)
treated for chronic LE (31 patients with autologous
US-guided PRP injection and 32 patients with US-guided
focal ESW therapy) at our institution, from February 2009
to October 2014. Inclusion criteria were (1) symptoms of
LE for more than 6 months and magnetic resonance ima-
ging (MRI) and/or US diagnosis of tendinosis of ERCB
tendon; (2) persistence of pain and function impairment
refractory to rest, ice, sling and pharmacological therapies
(local or systemic non-steroidal anti-inflammatory drugs
(NSAIDs) and/or analgesic drugs); (3) persistence of symp-
toms after previous physical therapies (Laser, Tecar, TENS
and US); and more than 6 months elapsed between the
selected treatment and previous therapies.
Patients in treatment using anti-inflammatory drugs/
pain killers, steroids or anticoagulant, cardiac pacemaker
carriers, previous injections, surgery or fractures of the
affected elbow, systemic diseases, history of epilepsy, con-
genital or acquired deformities of the upper limb, history of
neurologic or musculoskeletal disorders that might affect
grip strength, active/previous infection in the site of treat-
ment, open wounds or skin ulcers, history of any blood
disorder, haemoglobin <11 g/dL, haematocrit <33%, and
platelet count outside of the normal range of 150 to 400 
1000/mL and pregnant or lactating women were excluded.
Patients with less than 24-month follow-up were excluded
as well.
In all cases, diagnosis was verified before the treatment
by means of clinical tests, that is, a painful local palpation
at the humeral epicondyle and positive Cozen’s and middle
finger’s tests. Furthermore, the sonographic evaluation of
the elbow with high-frequency probe (18-6 MHz linear
transducer) was performed in all patients in order to con-
firm the diagnosis.
Patients were seated in a chair with the arm flexed at
90 and the antero-medial forearm resting on an examina-
tion bed. The common extensor origin from the lateral
humeral epicondyle was examined in longitudinal and
axial planes. The sonographic assessment was made with
systematic evaluation of tendon echotexture, overall ten-
don thickness and neovascularity as previously described
by Clarke et al.13
US inclusion findings were structural changes in the
common extensor origin (tendon thickening, hypoecho-
genicity and diffuse heterogeneity) and blood flow changes
or neovascularity.
Tendinosis was defined as thickening and heteroge-
neous echotexture of tendon with the presence of Doppler
hyperaemia in common extensor origin. Negative findings
on both grey scale and Doppler US conclusively excluded
diagnosis of LE. Patients diagnosed with myofascial pain,
posterior interosseous nerve entrapment and partial tears of
common extensor origin were excluded.
The patients were free to choose their treatment mod-
ality (PRP or ESW) based on their confidence and dispo-
sal, being informed and conscious of the advantage/
disadvantage of each treatment and always upon written
informed consent.
For patient treated with PRP injections, a blood sample
of 450 mL was taken from the patients and treated by the
Department of Transfusion Medicine. The blood under-
went a standardized protocol of preparation, which con-
sisted of three centrifugations (Hettich Zentrifugen®;
Hettich Lab technology, Tuttlingen, Germany): the first
at 3550 r/min for 12 min, the second at 1100 r/min for
10 min and the last at 2600 r/min for 20 min; the final
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product was then filtered and frozen (–80C) in four shares
for cryopreservation.
The platelet concentration in this type of PRP was 2–3
times greater than the blood platelet count (range 250,000–
900000/mL, mean 600,000/mL), which is considered to be
moderately elevated. Moderately elevated platelet concen-
tration seems to induce optimal biological benefit, with
lower platelet concentrations leading to suboptimal effects
and higher platelet concentrations to inhibitory effects.
During their preparation, leucocytes were filtered and their
concentration in the final product was low (<1000/mL).
Our institute protocol provides four 3-mL injections of
PRP once a week for each patient. The injection was always
performed in sterile conditions and under US guide. We
decided to use the sonography to better assess the soft
tissue target and because the manual injection of the ECRB
tendon often lacks accuracy with only 30% of reported hit
target tissue.14
For patients belonging to the ESW group, focal ESW
were administered by means of an electromagnetic genera-
tor equipped with in-line US guidance in order to increase
the reliability and effectiveness of the treatment (Minilith
SL1, Storz®, Tagerwilen, Switzerland).
In accordance with the literature15,16 and International
Society for Medical Shock wave Treatment guidelines,17
ESWs were administered during 3–4 weekly sessions,
depending on the symptom’s initial severity and symptoms
modification during treatment.
The repetition frequency of shock wave pulses was 4
Hz, and the machine was set on a low to medium energy
level compatible with patients’ pain tolerance. A low
energy level (0.03–0.07 mJ/mm2) in the first session, and
then medium energy level (0.08–0.13 mJ/mm2), if toler-
ated, during the following sessions was considered the stan-
dard protocol. A total of 1000 impulses were administered
for each session. The US guide was used to focalize the
ESW pulses at the muscle origin and muscle–tendon junc-
tion of the ECRB, which are both involved in the pathogen-
esis of the LE. Coherence with the localization of pain
generally complained by the patient was verified during
the ESW administration. This specific setting protocol was
demonstrated to be effective in the treatment of recalcitrant
LE in a previous studies.8,9
No local anaesthetic was used to prevent a possible
negative interaction. Patients were advised to rest, apply
ice and avoid unnecessary efforts for 24–48 h after the
treatment session. Acetaminophen was recommended as
an analgesic, if needed, but patients were instructed to
abstain from taking NSAIDs during the treatment and for
2 weeks after the last injection in order to prevent possible
negative interaction with the mechanism action of PRP.
Patients were also instructed to stop sports activity or
heavy physical work during the treatment time. Physical
therapy was not prescribed after treatment, and a gradual
return to normal recreational, working and sport activities
was then allowed.
All the included patients were evaluated by means of
Roles–Maudsley (RM) score,18 quick Disabilities of Arm,
Shoulder, and Hand (QuickDASH) score,19 visual analogic
scale (VAS)20 and patient-rated tennis elbow evaluation
(PRTEE)21 to retrospectively assess the pain relief, level
of activity, the self-reported function and subjective satis-
faction at long-term follow-up. The RM score is a subjec-
tive functional score ranging from 1 to 4 where 1
correspond to pain-free full movement and activity and 4
to poor painful function with limitation of daily activities
(Table 1).
The QuickDASH represents a validated self-reporting
questionnaire consisting of 11 questions (from the 30 items
of the original version), investigating symptoms and func-
tional tasks. Like the extended version, the QuickDASH
score ranges from 0 (no disability) to 100 (extreme disabil-
ity). The VAS indicates the subjective feeling of pain, with
0 indicating no pain and 10 indicating the worst pain that
the patient has ever had. The PRTEE is 15-item question-
naire designed to measure forearm pain and functional dis-
ability in patients with tennis elbow. The score ranges from
0 (best score) to100 (worst score).
Pretreatment data relative to RM, quickDASH, PRTTE,
VAS and clinical tests were available for all patients, con-
sulting medical records and values were compared with
those obtained at last follow-up (LFU).
Subjective satisfaction was investigated through
patients self-assessing to one of four satisfaction categories
(i.e. very satisfied with the outcome, satisfied, partially
satisfied and unsatisfied). A specifically created question-
naire was further used in order to investigate eventual
therapies tried before the treatment in study, time before
symptom remission after treatment, time prior to go back to
usual activities, need to retreatment or reinjection.
Recurrence was defined as persistence of pain or symp-
tom relapse with return to normal activities, work and/or
sport activities, need of reinjection/retreatment and recur-
rence of symptoms after minimum of 6 months after admi-
nistered therapy.
The continuous variables between the two-paired groups
were compared using the nonparametric Student’s t test or
the Wilcoxon signed-rank test. The continuous variables
between two-unpaired groups were compared with Mann–
Whitney U test. The categorical variables of two indepen-
dent groups were compared with the two-tailed Fisher’s
exact test. A p < 0.05 was considered statistically significant.
Table 1. RM score.
Results Point Interpretation
Excellent 1 No pain, full movement and activity
Good 2 Occasional discomfort, fullmovement and activity
Fair 3 Some discomfort after prolonged activity
Poor 4 Pain-limiting activities
RM: Roles–Maudsley.
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Results
Sixty-nine patients with LE diagnosis met the inclusion
criteria of the study, 6 of them were not disposable to
participate or were untraceable for a total of 63 investigated
patients (63 elbows).
Thirty-one patients were treated with autologous US-
guided PRP injections and 32 with US-guided ESW admin-
istration (Table 2). Twenty-six patients in the series were
considered at risk of LE for both their manual and sport
activities.
The mean age was 48.5 + 8.7 years (range, 18–65), and
the mean follow-up was 42.1 + 9.1 months (range, 24–67
months). No differences were found between the demo-
graphic characteristics of the two different treatment
groups (p > 0.05). The QuickDASH, VAS, RM and PRTEE
scores before the treatment and at LFU for both treatment
groups are reported in Table 3. Statistical analysis of data
demonstrated that both US-guided autologous PRP injec-
tion and US-guided focal ESW administration demon-
strated effective in chronic LE with significant
improvement in the QuickDASH, VAS, RM and PRTEE
scores (p < 0.0001) as shown in Figure 1.
Nevertheless, no differences were found for the final
results of the QuickDASH, VAS, RM and PRTEE scores
between the groups (p > 0.05). No differences were found
in recurrence rate between the two groups (6.5% in the PRP
group and 15.6% in the ESW group, p > 0.05). No adverse
effects or complications subsequent to treatment adminis-
tration were recorded in both groups.
The mean time between treatment and symptoms reso-
lution was 1.1 + 0.9 months (range, 0.5 – 6) for the PRP
treatment and 1.7 + 1.1 months (range, 0.5–4) for ESW
therapy (p ¼ 0.0212); furthermore, the mean time to return
to the normal activity of daily living was 0.8 + 1.4 months
(range, 0–6) for PRP group and 1.5 + 0.6 months for ESW
therapy (range, 0–3) (p ¼ 0.0119).
Two patients (6.4%) in the PRP group and four patients
(12.5%) in the ESW group were unsatisfied but no differ-
ences were found (p > 0.05), instead 88.9% of the patients
were satisfied and very satisfied with the chosen treatment.
Among patients treated with ESW therapy, one patients had
resolution of symptoms in the second session of therapy and
was satisfied at the LFU. Three patients (4.8%) required
surgical treatment (one in the PRP group and two in the
ESW group) for failure of conservative measures. Outcome
features of the two treatment groups are listed in Table 4.
Discussion
Various conservative measures have been proposed as suit-
able alternatives to surgical intervention for chronic tennis
elbow. Unfortunately, no guidelines are available for the
treatment of chronic LE. For many years, injection of cor-
ticosteroid has been the preferred treatment of patients with
recalcitrant LE.
Earlier studies suggested greater benefits of corticoster-
oid injection compared to NSAIDs, but the same cohort of
patients demonstrated no difference in pain control and
outcomes at 12 months.22 More recent studies suggested
that corticosteroid injections demonstrated only short-term
relief and that these patients may have more pain and dys-
function at longer follow-up compared to other patients
treated with conservative measures.23,24 Smidt et al.24
showed high frequency of relapse and recurrence with cor-
ticosteroid injection for LE because the inhibitor processes
of cortisone may lead the intra-tendinous injection to dele-
terious long-term effects with permanent structural changes
and tendon atrophy. Furthermore repeated preoperative
steroid injection have been recently identified as significant
risk factor for revision in case of surgical treatment of LE.25
When considering treatment modalities for patients
with LE, researchers have begun to examine the role of
biological therapies for LE management in an attempt to
optimize the local environment for tendon healing and to
promote its potential regeneration. Inflammation pro-
cesses can in fact provoke the release of cytokines and
growth factors from platelets, leucocytes, macrophages
and other inflammatory cells. These growth factors pro-
mote neovascularization and chemotaxis of fibroblasts
and tenocytes and stimulate fibroblast and tenocytes pro-
liferation and neo-synthesis of collagen.26 These pro-
cesses are based on the mechanism of action of both
PRP injection and ESW therapy.6,9,27
Peerbooms et al.28 compared a single PRP injection and
corticosteroid injection in patients who failed non-
operative measures and demonstrated significant pain
reduction and increased function with PRP injection ther-
apy. Authors obtained 73% of success rate, nevertheless the
PRP properties were different: Local anaesthetics and epi-
nephrine have been added, leucocyte concentration were
not clearly specified and therapeutic protocol was different
(all included patients received only one PRP injection).
These features could justify the differences in final results
if compared with the present study.


















PRP 31 18/13 14 8.3 + 4.3 46.3 + 10.1 18–69 44.5 + 11.9 25–67
ESW 32 13/19 12 7.9 + 5.1 50.4 + 7.3 31–65 40.0 + 5.1 24–45
PRP: platelet-rich plasma; ESW: extracorporeal shock wave.
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Mishra et al.11 published a prospective randomized con-
trolled trial of 230 patients and highlighted a meaningful
improvement in the clinical outcome in patients treated
with leucocyte-enriched PRP for LE after 24 weeks. The
success rate of this study was 82.1%, but both the PRP
preparation and the therapeutic protocol were different.
The non-standardized PRP preparation and composition
do not help in the comparison between the different PRP
products being delivered to patients. A precise, stepwise
and detailed description of the preparation protocol is
required to allow comparison among studies and provide
the reproducibility of this therapeutic application.29
Systematic reviews that had evaluated the effectiveness
and reliability of ESWT for the treatment of LE have been
published with diverging results.30 ESW therapy demon-
strated positive results in some studies.7,16 On the other
hand, some other studies did not find superiority to ESW
if compared with placebo.15,30
Positive effect of ESW therapy on LE have been demon-
strated by some authors to reduce the necessity of
surgery.15,31 ESW therapy (1000 impulses of 0.08 mJ/mm2)
represented an effective method to decrease pain in chronic
tennis elbow. Authors showed how the low-energy shock
wave treatment led to alleviation of pain and improvement
in function in 90% of their 50 patients with chronic tennis
elbow with 91% of resolution of symptoms in patients with
LE after treatment. Wang et al.9 demonstrated significant
improvement in pain, functional scores, grip strength and
range of motion among patients treated with 1000-impulse
protocol compared with the control group.
From our opinion, to obtain good results with the ESW
therapy for the treatment of LE, it is necessary to accurately
select the patients and to use focused ESW therapy. This
therapy has the maximal energy to reach the focus that is
located deeper into the soft tissues and the US guide is used
to identify the target tissue with less missing rate. However,
there is a need for high-quality studies comparing the
results of the focused and radial ESW therapy in chronic
LE.32
Biological impact of the shock waves on target tissues
are the up-regulation of proliferating cell nuclear antigen
(PCNA), collagen type I, collagen type III and TGF-b-1
gene expression, followed by an increases in nitric oxide
(NO) production, TGF-b-1 release and collagen synthesis.
Moreover, shock waves can stimulate tenocyte prolifera-
tion and collagen synthesis. These data supported that teno-
cyte proliferation is mediated by early up-regulation of
PCNA and TGF-b-1 gene expression, endogenous NO
release and synthesis and TGF-b-1 protein and then col-
lagen synthesis.26
In the present study, PRP injection and ESW therapy
both lead to significant improvement in pain, function and
return to normal activity in patients with chronic LE, with a
minimum of 2-year follow-up. Although this improvement
was comparable in both treatment groups for RM, quick-
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showed early remission of symptoms and faster return to
normal activity if compared with ESW therapy. To the best
of our knowledge, there are no study comparing the long-
term efficacy of these conservative treatments.
Several limitations could be underlined in this work.
First, it is a non-controlled retrospective study on limited
population of patients. Second, there is also a large varia-
bility in patients’ features and about symptom history and
previous conservative treatments. Third, the absence of
MRI and/or sonographic imaging evaluation at the LFU
to demonstrate the soft tissue differences before and after
treatment. Finally the high satisfaction rate of the present
study could be justified because the patient self-selected
their treatment modality. With these limitation, however,
this is a single-centre study with two groups of patients
with homogeneous diagnosis treated with standard proto-
cols and mid-term follow-up of at least 2 years.
Conclusion
PRP injection and ESW therapy both are feasible and
safe options for the treatment of chronic LE with low
risk of complications and with acceptable mid-term
follow-up results. Longer term randomized comparative
studies are necessary to determine more objectively the
correct definition of the first-line treatment for ESW and
PRP injections.
Figure 1. Graphic illustration of pretreatment and at LFU QuickDASH (a), VAS (b), RM (c) and PRTEE (d) scores of the two treatment
groups of patients. LFU: last follow-up; QuickDASH: Quick Disabilities of Arm, Shoulder, and Hand; VAS: visual analogic scale; PRTEE:
patient-rated tennis elbow evaluation; RM: Roles–Maudsley.
Table 4. Clinical features and p values indicating no statistically
significant differences of the two treatment groups of patients.
Results PRP ESW p Value
Adverse effects 0 0 1
Recurrence 2 5 0.426
Unsatisfied patients 2 4 0.672
Surgical treatment 1 2 0.202
PRP: platelet-rich plasma; ESW: extracorporeal shock wave.
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